AU2018221148B2 - 5-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same - Google Patents

5-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same Download PDF

Info

Publication number
AU2018221148B2
AU2018221148B2 AU2018221148A AU2018221148A AU2018221148B2 AU 2018221148 B2 AU2018221148 B2 AU 2018221148B2 AU 2018221148 A AU2018221148 A AU 2018221148A AU 2018221148 A AU2018221148 A AU 2018221148A AU 2018221148 B2 AU2018221148 B2 AU 2018221148B2
Authority
AU
Australia
Prior art keywords
optionally substituted
compound
alkyl
pharmaceutically acceptable
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2018221148A
Other languages
English (en)
Other versions
AU2018221148A1 (en
Inventor
Robert BORBO KARGBO
Aimee Crombie Speerschneider
Michael John Hawkins
Robert Jason Herr
Guodong Liu
Tamara Ann MISKOWSKI DAUBERT
Philip Michael Pitis
Donna Romero
Dennis Shinji Yamashita
Catherine C.K. Yuan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trevena Inc
Original Assignee
Trevena Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trevena Inc filed Critical Trevena Inc
Publication of AU2018221148A1 publication Critical patent/AU2018221148A1/en
Application granted granted Critical
Publication of AU2018221148B2 publication Critical patent/AU2018221148B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
AU2018221148A 2017-02-17 2018-02-15 5-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same Ceased AU2018221148B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762460407P 2017-02-17 2017-02-17
US62/460,407 2017-02-17
PCT/US2018/018312 WO2018152293A1 (en) 2017-02-17 2018-02-15 5-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same

Publications (2)

Publication Number Publication Date
AU2018221148A1 AU2018221148A1 (en) 2019-08-29
AU2018221148B2 true AU2018221148B2 (en) 2022-05-05

Family

ID=63169980

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018221148A Ceased AU2018221148B2 (en) 2017-02-17 2018-02-15 5-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same

Country Status (10)

Country Link
US (1) US11702408B2 (enExample)
EP (1) EP3582779B1 (enExample)
JP (1) JP7316216B2 (enExample)
KR (1) KR20190129867A (enExample)
CN (1) CN110520129A (enExample)
AU (1) AU2018221148B2 (enExample)
BR (1) BR112019016827A2 (enExample)
CA (1) CA3052480A1 (enExample)
IL (1) IL268414A (enExample)
WO (1) WO2018152293A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110520129A (zh) 2017-02-17 2019-11-29 特维娜有限公司 含有5元氮杂杂环的δ阿片受体调节化合物及其使用和制备方法
CN110446495B (zh) * 2017-02-17 2023-09-05 特维娜有限公司 含有7元氮杂杂环的δ阿片受体调节化合物及其使用和制备方法
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN110117245B (zh) * 2019-06-21 2021-03-02 浙江师范大学 一种jak抑制剂中间体的合成方法
US20220213061A9 (en) * 2020-02-25 2022-07-07 Tes Pharma S.R.L. Heterocyclic compounds for modulating nr2f6
CN116406268A (zh) 2020-10-27 2023-07-07 特维娜有限公司 δ-阿片样物质调节剂的结晶和无定形形式

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090042896A1 (en) * 2007-08-07 2009-02-12 Philippe Jablonski Pyrrolidine aryl-ether as nk3 receptor antagonists

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE352811B (enExample) 1971-06-04 1973-01-15 Pharmacia Ab
US3960150A (en) 1971-09-09 1976-06-01 Alza Corporation Bioerodible ocular device
US3867519A (en) 1972-04-27 1975-02-18 Alza Corp Bioerodible drug delivery device
SE375007B (enExample) 1972-11-30 1975-04-07 Pharmacia Ab
US3963025A (en) 1974-09-16 1976-06-15 Alza Corporation Ocular drug delivery device
JPS5825980B2 (ja) 1976-02-12 1983-05-31 ヤマサ醤油株式会社 サイクリックヌクレオチドの定量法
US4209514A (en) 1977-06-24 1980-06-24 Ciba-Geigy Corporation 3-Aminoalkyl-4-aryl-tetrahydroazepines
US4186184A (en) 1977-12-27 1980-01-29 Alza Corporation Selective administration of drug with ocular therapeutic system
US4303637A (en) 1980-04-04 1981-12-01 Alza Corporation Medication indicated for ocular hypertension
DK231088D0 (da) 1988-04-28 1988-04-28 Ferrosan As Piperidinforbindelser, deres fremstilling og anvendelse
CA1337418C (en) 1988-03-28 1995-10-24 Engelbert Ciganek 4-aryl-4-piperiding (or pyrrolidine or hexahydroazepine) carbinols and heterocyclic analogs thereof
US5086063A (en) 1988-03-28 1992-02-04 Du Pont Merck Pharmaceutical Company 4-aryl-4-piperidine (or pyrrolidine or hexahydroazepine) carbinols and heterocyclic analogs thereof
US5401629A (en) 1990-08-07 1995-03-28 The Salk Institute Biotechnology/Industrial Associates, Inc. Assay methods and compositions useful for measuring the transduction of an intracellular signal
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
HUP9902160A3 (en) 1996-03-29 2001-02-28 Pfizer Benzyl(idene)-lactam derivatives, their use as selective (ant)agonists of 5-ht1a-and/or 5-ht1d receptors, pharmaceutical compositions containing these compounds
JP2000513375A (ja) 1996-06-28 2000-10-10 メルク エンド カンパニー インコーポレーテッド フィブリノーゲンレセプター拮抗薬プロドラッグ
WO1998006694A1 (en) 1996-08-16 1998-02-19 Du Pont Pharmaceuticals Company Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof
AU4727799A (en) 1998-06-30 2000-01-17 Eli Lilly And Company Azepine derivatives having effects on serotonin related systems
TR200102911T2 (tr) 1999-04-09 2002-01-21 Astrazeneca Ab Adamantan türevleri.
AU1018801A (en) 1999-10-29 2001-05-14 Novo Nordisk A/S Use of 3,4-substituted piperidines
GB0015562D0 (en) 2000-06-23 2000-08-16 Pfizer Ltd Heterocycles
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
US20020077323A1 (en) 2000-07-12 2002-06-20 Mclean Stafford Use of delta opioid receptor ligands and serotonin reuptake inhibitors in the treatment of chemical dependencies
US6476046B1 (en) 2000-12-04 2002-11-05 Sepracor, Inc. Diazabicyclo[4.3.0]nonanes, and methods of use thereof
US6995144B2 (en) 2002-03-14 2006-02-07 Eisai Co., Ltd. Nitrogen containing heterocyclic compounds and medicines containing the same
PT2208727E (pt) 2002-09-19 2012-10-11 Lilly Co Eli Éteres diarílicos como antagonista do receptor opióide
JP2006517567A (ja) 2003-02-12 2006-07-27 ニューロサーチ、アクティーゼルスカブ 新規８−アザ−ビシクロ［３．２．１］オクタン誘導体及びこれをモノアミン神経伝達物質再取り込み阻害薬として使用する方法
WO2005012716A1 (en) 2003-07-25 2005-02-10 Siemens Vdo Automotive Inc. Integrated vapor control valve and sensor
JP2007507504A (ja) 2003-09-30 2007-03-29 メルク　エンド　カムパニー　インコーポレーテッド フェニルピロリジンエーテル系タキキニン受容体拮抗薬
WO2005068427A1 (ja) 2004-01-14 2005-07-28 Takeda Pharmaceutical Company Limited カルボキサミド誘導体およびその用途
CA2569611C (en) 2004-06-21 2012-12-11 F. Hoffmann-La Roche Ag Indole derivatives as histamine receptor antagonists
DE602005023172D1 (de) 2004-07-16 2010-10-07 Schering Corp Hydantoinderivate zur behandlung von entzündlichen erkrankungen
US7488745B2 (en) 2004-07-16 2009-02-10 Schering Corporation Compounds for the treatment of inflammatory disorders
US7504424B2 (en) 2004-07-16 2009-03-17 Schering Corporation Compounds for the treatment of inflammatory disorders
US7098203B2 (en) 2004-07-20 2006-08-29 Bristol-Myers Squibb Company Homopiperidine derivatives as NK-1 antagonists
US7138423B2 (en) 2004-07-20 2006-11-21 Bristol-Myers Squibb Company Arylpyrrolidine derivatives as NK-1 /SSRI antagonists
US7872023B2 (en) 2005-02-17 2011-01-18 Research Triangle Institute Kappa opioid receptor ligands
TW200804307A (en) 2005-10-27 2008-01-16 Synta Pharmaceuticals Corp Process for preparing mesylate salts of IL-12 inhibitory compounds
CA2631221C (en) 2005-12-01 2014-06-03 F. Hoffmann-La Roche Ag Serotonin transporter (sert) inhibitors
US20070142389A1 (en) 2005-12-20 2007-06-21 Pfizer Inc. Piperidine derivatives
AU2007225208A1 (en) 2006-03-14 2007-09-20 Amgen Inc. Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
WO2008012623A1 (en) 2006-07-25 2008-01-31 Pfizer Products Inc. Benzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor
US8470361B2 (en) 2006-12-04 2013-06-25 Orexo Ab Non-abusable pharmaceutical composition comprising opioids
KR20100017372A (ko) 2007-05-25 2010-02-16 애보트 게엠베하 운트 콤파니 카게 향대사성 글루타메이트 수용체 2（ｍｇｌｕ2 수용체）의 포지티브 조절자로서의 헤테로사이클릭 화합물
AU2008290634B2 (en) 2007-08-22 2012-12-06 F. Hoffmann-La Roche Ag Pyrrolidine aryl-ether as NK3 receptor antagonists
GB0721178D0 (en) 2007-10-29 2007-12-05 Glaxo Group Ltd Chemical compounds
EA201000808A1 (ru) 2007-11-16 2011-04-29 Ньюраксон, Инк. Индольные соединения и способы лечения висцеральной боли
WO2009072643A1 (en) 2007-12-03 2009-06-11 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound and use thereof
US8394834B2 (en) 2009-08-25 2013-03-12 Hoffman-La Roche Inc. Pyrrolidines as NK3 receptor antagonists
BR112012010253A8 (pt) 2009-10-30 2016-10-04 Janssen Pharmaceutica Nv compostos de pirimidina como moduladores do receptor delta opioide
CN102753528A (zh) 2009-12-04 2012-10-24 霍夫曼-拉罗奇有限公司 作为单胺重摄取抑制剂的二苯基氮杂*衍生物
US8664214B2 (en) 2010-03-30 2014-03-04 AbbVie Deutschland GmbH & Co. KG Small molecule potentiators of metabotropic glutamate receptors I
US8507535B2 (en) * 2010-07-07 2013-08-13 Hoffmann-La Roche Inc. Methyl-pyrrolidine ether derivatives
WO2012075232A1 (en) 2010-12-04 2012-06-07 Trevena, Inc. Opioid receptor ligands and methods of using and making the same
ES2716865T3 (es) 2011-02-18 2019-06-17 Scripps Research Inst Diferenciación dirigida de células precursoras de oligodendrocitos a un destino celular mielinizante
ME02754B (me) 2011-03-23 2018-01-20 Trevena Inc Ligandi opioidnih receptora i postupci njihove upotrebe i pripreme
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
JP2014159375A (ja) 2011-06-15 2014-09-04 Takeda Chem Ind Ltd アゼパン化合物
ES2586213T3 (es) 2011-10-31 2016-10-13 Xenon Pharmaceuticals Inc. Compuestos de bencenosulfonamida y su uso como agentes terapéuticos
WO2013182612A1 (en) 2012-06-07 2013-12-12 Bayer Pharma Aktiengesellschaft Glucose transport inhibitors
JP6250668B2 (ja) 2012-08-10 2017-12-20 ヤンセン・サイエンシズ・アイルランド・ユーシー 新しい抗菌化合物
BR112015022758A2 (pt) 2013-03-15 2017-07-18 Abbvie Deutschland derivados de pirrolidina, composições farmacêuticas contendo os mesmos e seu uso em terapia
WO2016029218A1 (en) 2014-08-22 2016-02-25 The Arizona Board Of Regents On Behalf Of The University Of Arizona Substituted 1-arylethyl-4-acylaminopiperidine derivatives as opioid/alpha-adrenoreceptor modulators and method of their preparation
WO2016210403A1 (en) 2015-06-26 2016-12-29 The Regents Of The University Of Michigan G protein-coupled receptor kinase inhibitors and methods for use of the same
MA43313B1 (fr) 2015-09-02 2022-06-30 Trevena Inc Aza-hétérocyclique à 6 éléments contenant des composés modulateurs de récepteurs opioïdes delta, et leurs procédés de fabrication et d'utilisation
CN110520129A (zh) 2017-02-17 2019-11-29 特维娜有限公司 含有5元氮杂杂环的δ阿片受体调节化合物及其使用和制备方法
CN110446495B (zh) 2017-02-17 2023-09-05 特维娜有限公司 含有7元氮杂杂环的δ阿片受体调节化合物及其使用和制备方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090042896A1 (en) * 2007-08-07 2009-02-12 Philippe Jablonski Pyrrolidine aryl-ether as nk3 receptor antagonists

Also Published As

Publication number Publication date
JP2020508300A (ja) 2020-03-19
IL268414A (en) 2019-09-26
JP7316216B2 (ja) 2023-07-27
AU2018221148A1 (en) 2019-08-29
BR112019016827A2 (pt) 2020-04-07
WO2018152293A1 (en) 2018-08-23
CN110520129A (zh) 2019-11-29
CA3052480A1 (en) 2018-08-23
US11702408B2 (en) 2023-07-18
KR20190129867A (ko) 2019-11-20
US20210061790A1 (en) 2021-03-04
EP3582779A4 (en) 2020-07-29
EP3582779A1 (en) 2019-12-25
EP3582779B1 (en) 2024-04-17

Similar Documents

Publication Publication Date Title
EP3582779B1 (en) 5-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
US20230203002A1 (en) 6-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
US11912713B2 (en) 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
KR20250102067A (ko) 소마토스타틴 수용체 서브타입 4 (sstr4) 작용제 및 그의 응용
US20230303531A1 (en) 5-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
HK40083469A (en) 6-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
HK40016700A (en) 5-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
HK1257927B (en) 6-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
BR112018004154B1 (pt) Compostos moduladores do receptor delta opioide contendo azaheterocíclicos de 6 membros, composições compreendendo os mesmos e seus usos

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired